ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 171

Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients

Jana Hurnakova1, Jakub Zavada1, Petra Hanova1, Hana Hulejová1, Martin Klein1, Herman F Mann1, Olga Sleglova1, Marta Olejarova1, Šárka Forejtová1, Olga Ruzickova1, Martin Komarc2, Jiri Vencovsky1, Karel Pavelka1 and Ladislav Senolt1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Biophysics and Informatics of the First Faculty of Medicine, Charles University, Prague, Czech Republic

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Biomarkers, Disease Activity, rheumatoid arthritis (RA) and ultrasonography

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Calprotectin (S100A8/9, MRP8/14) has been demonstrated as a promising biomarker of clinical and laboratory disease activity in rheumatoid arthritis (RA). In addition, two small previous studies have shown that calprotectin might by associated with ultrasound-determined synovitis 1,2. The aim was to evaluate associations between calprotectin and conventional disease markers as well as ultrasound parameters of disease activity in a larger cohort of RA patients.

Methods:

A total of 160 patients with RA (128 females, median disease duration 4.8 years) were recruited in this study. All patients underwent clinical (DAS28, CDAI, SDAI) and ultrasound examination (German US-7 score) 3. The levels of serum calprotectin and CRP were measured at the time of ultrasound assessment. Clinical and laboratory measures were correlated with ultrasound findings using Spearman´s correlation coefficient. Multiple regression analysis was used to determine the predictive value of calprotectin, CRP and DAS28 to determine GS and PD synovitis scores.

Results:

We found that calprotectin was significantly associated with DAS28 (r=0.332, p<0.001), SDAI (r=0.318, p<0.001), CDAI (r=0.294, p<0.001) and particularly with CRP levels (r=0.551, p<0.001). Moreover, calprotectin significantly correlated with GS (r=0.366, p<0.001) and PD synovitis scores (r=0.350, p<0.001). In multiple regression analysis, DAS28 and calprotectin, but not CRP, were strong predictors of GS (β=0.598, p<0.001; β=0.371, p<0.001, resp.) (adjusted R2=0.680) and PD synovitis scores (β=0.379, p<0.001; β=0.346, p<0.001, resp.) (adjusted R2=0.633).

Conclusion:

Calprotectin is associated with clinical, laboratory and ultrasound parameters of synovial inflammation and may have an additional role in monitoring disease activity in RA.

References:

  1. Hammer HB, Fagerhol MK, Wien TN, Kvien TK. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab. Arthritis Res Ther. 2011;13(5):R178.
  2. Hurnakova J, Hanova P, Hulejova H, et al. Serum calprotectin (S100A8/9) correlates with clinical and ultrasound outcomes in patients with early rheumatoid arthritis. In Ann Rheum Dis. 2014; Suppl (2): 658–658.
  3. Backhaus TM, et al. The US7 score is sensitive to change in a large cohort of patients with rheumatoid arthritis over 12 months of therapy. Ann Rheum Dis. 2013 Jul;72(7):1163-9.

Disclosure: J. Hurnakova, None; J. Zavada, None; P. Hanova, None; H. Hulejová, None; M. Klein, None; H. F. Mann, None; O. Sleglova, None; M. Olejarova, None; Forejtová, None; O. Ruzickova, None; M. Komarc, None; J. Vencovsky, None; K. Pavelka, None; L. Senolt, None.

To cite this abstract in AMA style:

Hurnakova J, Zavada J, Hanova P, Hulejová H, Klein M, Mann HF, Sleglova O, Olejarova M, Forejtová , Ruzickova O, Komarc M, Vencovsky J, Pavelka K, Senolt L. Serum Calprotectin Levels Correlate with Ultrasonographic Synovitis in Rheumatoid Arthritis Patients [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/serum-calprotectin-levels-correlate-with-ultrasonographic-synovitis-in-rheumatoid-arthritis-patients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-calprotectin-levels-correlate-with-ultrasonographic-synovitis-in-rheumatoid-arthritis-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology